RxDoctor Payments Data

Amanda Hemphill

Family · Creve Coeur, MONPI 1073973863

Payments from drug & device makers

$1,217in general payments, 2019–2025

Across 54 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$615
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$406
  • Avanir Pharmaceuticals, Inc.$136
  • AbbVie$33
  • Johnson & Johnson$15
  • Vanda Pharmaceuticals Inc.$12

What the payments were for

  • Food & beverage$1,05987%
  • Education$15813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,217 in reported general payments places this provider in the 70th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$221,445
Medicare patients
1,106
Services billed
3,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine76$338,388
CaplytaLumateperone Tosylate112$96,172
IngrezzaValbenazine Tosylate12$89,343
RexultiBrexpiprazole125$67,520
PerserisRisperidone14$35,446
Paliperidone ErPaliperidone159$23,936
VraylarCariprazine Hcl22$21,181
Aripiprazole558$19,783
Risperidone ErRisperidone Microspheres21$18,271
SecuadoAsenapine11$16,185
Divalproex Sodium313$13,758
Clozapine168$12,451
Quetiapine Fumarate921$11,001
Buspirone Hcl1,164$10,925
Duloxetine Hcl361$8,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$615$338,38876 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$406$96,172112 claims
AbbVieVraylar$33$21,18122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,812 family providers in Missouri.

Other family in Creve Coeur

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →